Cardiovascular cryoablation tech developer Adagio Medical said it launched its One Shot+ cryoablation catheter, and that the first patient has been treated with the device.
The Laguna Hills, Calif.-based company said the newly cleared One Shot+ catheter is intended for pulmonary vein isolation and other continuous ablation lesions of non-pulmonary-vein targets for treating atrial fibrillation.
“This technology allows me to provide a very efficient treatment to my patients. I am very pleased to see that with this latest generation of Adagio’s cryoablation catheter, I can achieve complete PVI considerably faster than with other treatment modalities with unsurpassed efficacy. The new adjustable diagnostic capacity simplifies the procedure and makes it much less operator-dependent. I am looking forward to performing more cases with this device,” Dr. Tom de Potter of Aalst, Belgium’s OLV Hospital said in a prepared statement.
The One Shot+ is designed for use in a transseptal procedure to create continuous and focal transmural lesions on the left and right atrium. The catheter incorporates diagnostic electrodes for navigation to the ablation site and real-time monitoring of electrograms to confirm lesion creation, the company said.
The newly launched catheter has been used to create transmural lesions throughout the atrial endocardium including the pulmonary vein antrum, posterior wall, mitral isthmus, cavo-tricsupid isthmus and identified target drivers, Adagio said.
“Adagio has been developing the ultra-low temperature cryoablation technology for nearly seven years and has proven that it produces very promising clinical outcomes. Lately, our focus has been on making this technology even more physician friendly and easier to use, while maintaining its superior clinical capabilities. The new One Shot+ catheter was designed to enable the clinician to isolate all pulmonary veins with continuous transmural lesions in under 20 minutes of total dwell time. We’re very pleased that this goal has already been realized in several of these cases,” Adagio CEO Olav Bergheim said in a press release.